Revvity Partners with Lilly to Expand Access to AI Drug Discovery Models

Revvity Inc. has partnered with Eli Lilly to enhance access to Lilly's AI drug discovery models via Revvity's Signals platform. This collaboration aims to facilitate AI adoption in biotech by co-funding access for select participants, allowing organizations to use Lilly's models while maintaining data privacy. The initiative supports federated learning, enabling small and midsize biotechs to contribute data and improve AI-driven drug discovery outcomes.